IMR Press / RCM / Volume 23 / Issue 3 / DOI: 10.31083/j.rcm2303106
Open Access Review
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease
Show Less
1 Internal Medicine Unit, Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli", Piazza L. Miraglia, 80138 Naples, Italy
2 Department of Internal Medicine, Betania Evangelical Hospital, Via Argine, 80147 Naples, Italy
3 Facility of Epidemiology and Biostatistics, Gemelli Generator, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
4 Division of Cardiology, A.O.R.N. “Sant'Anna e San Sebastiano", Caserta, Italy
5 Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli", 80138 Naples, Italy
*Correspondence: (Riccardo Nevola)
Academic Editors: Massimo Volpe, Filippos Triposkiadis, Grigorios Korosoglou and Matteo Cameli
Rev. Cardiovasc. Med. 2022, 23(3), 106;
Submitted: 2 December 2021 | Revised: 1 January 2022 | Accepted: 6 January 2022 | Published: 17 March 2022
(This article belongs to the Special Issue State-of-the-Art Cardiovascular Medicine in Europe 2022)
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Type 2 Diabetes Mellitus (T2DM) is associated with an elevated incidence of cardiovascular and renal diseases, responsible for mortality rates significantly higher than in the general population. The management of both cardiovascular risk and progression of kidney disease thus seem crucial in the treatment of the diabetic patient. The availability of new classes of drugs which positively affect both cardiovascular and renal risk, regardless of the glycemic control, represents a revolution in the treatment of T2DM and shifts the attention from the intensive glycemic control to a holistic management of the diabetic patient. Among these, sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been associated with a remarkable reduction of cardiovascular and renal mortality, lower hospitalization rates for heart failure and lower progression of renal damage and albuminuria. Thus, their use in selected subpopulations seems mandatory. Aim of this review was the assessment of the current evidence on SGLT2i and their related impact on the cardiovascular and renal profiles.

heart failure
chronic kidney disease
Fig. 1.
Back to top